<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522077</url>
  </required_header>
  <id_info>
    <org_study_id>17-132</org_study_id>
    <nct_id>NCT03522077</nct_id>
  </id_info>
  <brief_title>RAVE: Radial Artery Vascular Complication and Resource Utilization</brief_title>
  <official_title>RAVE: Radial Artery Vascular Complication and Resource Utilization in Subjects Undergoing an Angiogram/PCI (Percutaneous Coronary Intervention)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurora Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chitogen, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aurora Health Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this open label study is to compare the rate of vascular
      complications associated with the use of the SoftSeal®-STF hemostatic pad in subjects
      undergoing transradial catherization when compared to the VascBand™ Hemostat. Patients will
      be randomized after radial access is achieved in 1:1 for each group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SoftSeal-STF hemostatic pad and VascBand Hemostat both function to stop bleeding without
      obstructing radial artery flow, and have been shown to reduce the occurrence of radial artery
      occlusion.

      The SoftSeal-STF hemostatic pad is an FDA-approved, chitosan-based, non-woven pad with a
      unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like
      synthetic clot. Its mechanism of action is believed to be due to bioadhesion between the
      chitosan polymer chains, which are positively charged, and the negatively charged blood and
      tissue components, thereby stopping bleeding.

      The VascBand Hemostat is an FDA-approved compression device designed to assist hemostasis of
      arterial, venous and hemodialysis percutaneous access sites. It does this by applying
      pressure to stop bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of acute radial artery occlusion</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of subjects who experience radial artery occlusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to hemostasis</measure>
    <time_frame>1 day</time_frame>
    <description>The time interval in minutes beginning with sheath removal and ending with removal of hemostatic device and/or observed hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to discharge</measure>
    <time_frame>1 day</time_frame>
    <description>Time interval in minutes beginning with sheath removal and ending with patient discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major access site bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>A ≥ 3 mg/dL drop in hemoglobin, or required blood transfusion or vascular repair to control bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor access site bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>Light bleeding without hematoma formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor access site bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Light bleeding without hematoma formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma formation</measure>
    <time_frame>1 day</time_frame>
    <description>≥ 3 cm in diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global discomfort</measure>
    <time_frame>1 day</time_frame>
    <description>Subject reported global discomfort due to procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject reported discomfort</measure>
    <time_frame>1 day</time_frame>
    <description>At access site due to application of hemostatic device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Pain at access site on numeric scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS)</measure>
    <time_frame>30 days</time_frame>
    <description>Pain at access site on numeric scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of hand/digit ischemia</measure>
    <time_frame>1 day</time_frame>
    <description>Pain, tingling, or numbness in the hand and/or fingers reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of hand/digit ischemia</measure>
    <time_frame>30 days</time_frame>
    <description>Pain, tingling, or numbness in the hand and/or fingers reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>30 days</time_frame>
    <description>Vascular complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bruising, swelling, or redness</measure>
    <time_frame>30 days</time_frame>
    <description>At or near access site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">766</enrollment>
  <condition>Angiogram</condition>
  <condition>Percutaneous Coronary Intervention</condition>
  <arm_group>
    <arm_group_label>SoftSeal®-STF hemostatic pad</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The SoftSeal®-STF hemostatic pad will be applied over the radial access site and then will apply constant pressure for a period of 1 minute per French size if ACT &lt; 170, 2 minutes per French size if ACT 170-220, or 15 minutes if ACT &gt;220.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VascBand™ Hemostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The device will be placed proximal to the puncture site and inflated slowly until hemostasis is obtained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SoftSeal®-STF hemostatic pad</intervention_name>
    <description>Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot</description>
    <arm_group_label>SoftSeal®-STF hemostatic pad</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VascBand™ Hemostat</intervention_name>
    <description>Compression device to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites</description>
    <arm_group_label>VascBand™ Hemostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for an angiogram/PCI

          -  Planned transradial approach

        Exclusion Criteria:

          -  Evidence of impaired dual perfusion to the hand when tested using Allen's test

          -  Inaccessible radial arteries due to anatomic variations

          -  Infection or other skin disorder at the puncture site

          -  Undergoing an emergent or unplanned angiogram using the transradial approach

          -  Evidence of severe cognitive impairment or inability to understand the study
             procedures and answer follow-up questions

          -  Known sensitivity or allergic reaction to materials in the study devices

          -  Unwilling to participate in the study and follow all study-related procedures

          -  Participating physician deems the subject to not be a good candidate

          -  Inability to achieve radial access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad F Jan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aurora Health Care</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Cooper, RN, CCRC</last_name>
    <phone>414-385-2504</phone>
    <email>jennifer.cooper@aurora.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katie Stankowski, BSN, RN</last_name>
    <phone>414-385-2501</phone>
    <email>katie.Stankowski@aurora.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Stankowski</last_name>
      <phone>414-385-2501</phone>
      <email>katie.Stankowski@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Muhammad F Jan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angiogram</keyword>
  <keyword>Hemostatic</keyword>
  <keyword>Activated clotting time</keyword>
  <keyword>Quality of Life</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

